Business
InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation
InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa (HS)To broaden signal-finding activities for izicopan in additional I&I (inflammation and immunology) indications, InflaRx intends to conduct a PK bridging study in China in 2026 to enable expedited proof of concept studies in China and additional geographiesToward the goal of fast-tracking izicopan development across all applicable I&I indications, InflaR
About this update from Inflarx N.v.
[{"type":"image","alt":"InflaRx N.V.","displaySize":"","headline":null,"caption":"InflaRx N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/105c0226a90fc647941f68c2de55213a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lqiU0gFIS0tiIdhYPTjZSw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/105c0226a90fc647941f68c2de55213a","width":300,"height":157}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa (HS)","length":146,"tagName":"p"}]},{"val":[{"type":"text","content":"To broaden signal-finding activities for izicopan in additional I&I (inflammation and immunology) indications, InflaRx intends to conduct a PK bridging study in China in 2026 to enable expedited proof of concept studies in China and additional geographies","length":259,"tagName":"p"}]},{"val":[{"type":"text","content":"Toward the goal of fast-tracking izicopan development across all applicable I&I indications, InflaRx continues its concurrent strategy to foster discussions with potential collaborators","length":189,"tagName":"p"}]},{"val":[{"type":"text","content":"InflaRx is executing an approximately 30% workforce reduction, leading to a significant reduction of the Company’s cost structure, and extension of its cash runway to mid-2027","length":175,"tagName":"p"}]},{"val":[{"type":"text","content":"The Company intends to host a virtual Capital Markets Day to highlight the clinical utility and commercial potential of izicopan in HS and I&I broadly in spring 2026","length":169,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":938,"olType":false},{"type":"text","content":"JENA, Germany, Jan. 08, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is undertaking measures to reduce spending, extend the Company’s cash runway, and align resources to enable further development of izicopan in HS and other I&I indications as a potential best-in-class C5aR inhibitor and pipeline-in-a-product.","length":449,"tagName":"p"},{"type":"text","co...